공시 • Feb 25
Anterogen.Co.,Ltd., Annual General Meeting, Mar 20, 2026 Anterogen.Co.,Ltd., Annual General Meeting, Mar 20, 2026, at 09:01 Tokyo Standard Time. Location: conference room, 65, magokjungang 2-ro, gangseo-gu, seoul South Korea New Risk • Dec 02
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 8.1% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (8.1% average weekly change). Revenue is less than US$5m (₩7.3b revenue, or US$5.0m). New Risk • Jul 08
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 9.8% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. This is currently the only risk that has been identified for the company. 공시 • Feb 21
Anterogen.Co.,Ltd., Annual General Meeting, Mar 21, 2025 Anterogen.Co.,Ltd., Annual General Meeting, Mar 21, 2025, at 09:00 Tokyo Standard Time. Location: conference room, 65, magokjungang 2-ro, gangseo-gu, seoul South Korea New Risk • Feb 03
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 11% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (11% average weekly change). Revenue is less than US$5m (₩7.0b revenue, or US$4.7m). 공시 • Jan 23
Anterogen.Co.,Ltd. announced that it expects to receive KRW 5.0000314 billion in funding Anterogen.Co.,Ltd. announced a private placement of 274,727 common shares at a price of KRW 18,200 for gross proceeds of KRW 5,000,031,400 on January 23, 2025. The transaction includes participation from Horizon Flowkai Venture Fund subscribed for 241,759 shares and Horizon Flow No. 1 PEF subscribed for 32,968 shares. The transaction has been approved by the board of directors of the company. The payment date of the transaction is January 31, 2025. The transaction is subject to lockup for one year from the date of deposit. The company will issue shares of par value of KRW 500 per share through third party allocation capital increase method. New Risk • Nov 14
New minor risk - Market cap size The company's market capitalization is less than US$100m. Market cap: ₩140.4b (US$100.0m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 4.6% per year over the past 5 years. Minor Risks Revenue is less than US$5m (₩6.7b revenue, or US$4.7m). Market cap is less than US$100m (₩140.4b market cap, or US$100.0m). New Risk • Aug 05
New minor risk - Market cap size The company's market capitalization is less than US$100m. Market cap: ₩130.4b (US$95.6m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 9.4% per year over the past 5 years. Minor Risks Revenue is less than US$5m (₩6.5b revenue, or US$4.8m). Market cap is less than US$100m (₩130.4b market cap, or US$95.6m). New Risk • Apr 17
New minor risk - Market cap size The company's market capitalization is less than US$100m. Market cap: ₩137.4b (US$99.3m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 13% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (9.9% average weekly change). Revenue is less than US$5m (₩6.5b revenue, or US$4.7m). Market cap is less than US$100m (₩137.4b market cap, or US$99.3m). New Risk • Apr 04
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 9.0% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 13% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (9.0% average weekly change). Revenue is less than US$5m (₩6.5b revenue, or US$4.8m). New Risk • Feb 05
New minor risk - Market cap size The company's market capitalization is less than US$100m. Market cap: ₩132.3b (US$99.4m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 15% per year over the past 5 years. Minor Risks Revenue is less than US$5m (₩6.3b revenue, or US$4.7m). Market cap is less than US$100m (₩132.3b market cap, or US$99.4m). New Risk • Oct 06
New minor risk - Market cap size The company's market capitalization is less than US$100m. Market cap: ₩131.3b (US$97.5m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 18% per year over the past 5 years. Minor Risks Revenue is less than US$5m (₩6.2b revenue, or US$4.6m). Market cap is less than US$100m (₩131.3b market cap, or US$97.5m). Reported Earnings • May 16
First quarter 2023 earnings released: EPS: ₩4.00 (vs ₩273 loss in 1Q 2022) First quarter 2023 results: EPS: ₩4.00 (up from ₩273 loss in 1Q 2022). Net income: ₩37.4m (up ₩2.65b from 1Q 2022). Over the last 3 years on average, earnings per share has increased by 14% per year but the company’s share price has fallen by 19% per year, which means it is significantly lagging earnings. Reported Earnings • Mar 03
Full year 2022 earnings released: ₩706 loss per share (vs ₩59.00 loss in FY 2021) Full year 2022 results: ₩706 loss per share (further deteriorated from ₩59.00 loss in FY 2021). Net loss: ₩6.84b (loss widened ₩6.28b from FY 2021). Over the last 3 years on average, earnings per share has increased by 13% per year but the company’s share price has fallen by 17% per year, which means it is significantly lagging earnings. Reported Earnings • Nov 16
Third quarter 2022 earnings released: ₩155 loss per share (vs ₩43.00 loss in 3Q 2021) Third quarter 2022 results: ₩155 loss per share (further deteriorated from ₩43.00 loss in 3Q 2021). Net loss: ₩1.51b (loss widened 274% from 3Q 2021). Over the last 3 years on average, earnings per share has increased by 13% per year but the company’s share price has fallen by 28% per year, which means it is significantly lagging earnings. 공시 • Mar 09
Anterogen.Co.,Ltd. announced that it has received KRW 16 billion in funding from Shinhan Venture Investment Co, Ltd., NH Investment & Securities Co., Ltd., Investment Arm, SL Investment On March 8, 2021, Anterogen.Co.,Ltd. (KOSDAQ:A065660) closed the transaction. The company issued round 5 unregistered unguaranteed unsecured convertible bonds. 공시 • Feb 09
Anterogen.Co.,Ltd., Annual General Meeting, Mar 19, 2021 Anterogen.Co.,Ltd., Annual General Meeting, Mar 19, 2021, at 09:00 Korea Standard Time. Is New 90 Day High Low • Dec 20
New 90-day high: ₩55,200 The company is up 4.0% from its price of ₩53,300 on 21 September 2020. The South Korean market is up 14% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is up 7.0% over the same period. Reported Earnings • Nov 18
Third quarter 2020 earnings released: EPS ₩110 Third quarter 2020 results: Net income: ₩983.9m (up ₩1.46b from 3Q 2019). Over the last 3 years on average, earnings per share has fallen by 87% per year but the company’s share price has increased by 6% per year, which means it is well ahead of earnings. Is New 90 Day High Low • Oct 22
New 90-day low: ₩46,550 The company is down 30% from its price of ₩66,800 on 24 July 2020. The South Korean market is up 7.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is down 10.0% over the same period.